ESC 365 - Efficacy of pulmonary hypertension-targeted drugs for severe chronic thromboembolic pulmonary hypertension

ESC Premium Access

Efficacy of pulmonary hypertension-targeted drugs for severe chronic thromboembolic pulmonary hypertension

Session: New concepts in pulmonary hypertension

Topic: Intervention

Speaker: Doctor K. Takeuchi (Tokyo, JP)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Doctor Kaori Takeuchi

Tokyo (Japan)

0 follower

5 more presentations in this session

Validation of ESC/ERS 2015 guidelines risk score in patients with scleroderma associated pulmonary arterial hypertension (SSc-PAH)

Speaker: Doctor H. Fayed (London, GB)

Blood viscosity and its relevance to the diagnosis and management of pulmonary hypertension: a new elephant in the cathlab

Speaker: Doctor A. Kempny (London, GB)

Upfront triple combination therapy with ambrisentan, tadalafil and subcutaneous treprostinil in incident patients with severe pulmonary arterial hypertension

Speaker: Doctor M. D'Alto (Naples, IT)

Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities

Speaker: Professor S. Rosenkranz (Cologne, DE)

Waitlist outcomes for Eisenmengers patients listed for bilateral sequential lung transplant or heart-lung transplant

Speaker: Doctor K. Kearney (Sydney, AU)

Access the full session

New concepts in pulmonary hypertension

Speakers: Doctor K. Takeuchi, Doctor H. Fayed, Doctor A. Kempny, Doctor M. D'Alto, Professor S. Rosenkranz...

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources